Here, the study reports a novel cereblon‐based AR degrader, UBX‐390, and demonstrates its superior activity over established AR degraders, such as ARV‐110 or ARCC‐4, in prostate cancer cells under short‐ and long‐term treatment conditions. This evidence concerns the gene AR and prostate cancer.